Figure 3.
Clinical benefits achieved in the IMPROVE-IT trial (∗primary end point was a combination of CV death/major CV event and nonfatal stroke; #nonsignificant. There was no difference in CV death and unstable angina).
Clinical benefits achieved in the IMPROVE-IT trial (∗primary end point was a combination of CV death/major CV event and nonfatal stroke; #nonsignificant. There was no difference in CV death and unstable angina).